Integer (NYSE:ITGR) Shares Gap Down Following Weak Earnings

Integer Holdings Corporation (NYSE:ITGR) gapped down before the market opened on Thursday following a dissappointing earnings announcement. The stock had previously closed at $83.67, but opened at $77.05. Integer shares last traded at $86.4950, with a volume of 300,510 shares changing hands.

The medical equipment provider reported $1.20 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.21 by ($0.01). Integer had a net margin of 7.64% and a return on equity of 12.83%. The business had revenue of $439.58 million for the quarter, compared to the consensus estimate of $426.48 million. During the same quarter in the prior year, the business posted $1.31 earnings per share. Integer’s revenue for the quarter was up .5% on a year-over-year basis. Integer has set its FY 2026 guidance at 5.830-6.400 EPS.

Key Headlines Impacting Integer

Here are the key news stories impacting Integer this week:

• Positive Sentiment: Piper Sandler reaffirmed an “overweight” rating and raised its price target to $97, signaling upside potential and institutional confidence in Integer’s longer‑term prospects. Piper Sandler Rating
• Positive Sentiment: Integer’s board initiated a strategic review (including potential sale, merger or other combinations) to maximize shareholder value — a catalyst that can unlock premium bids or strategic alternatives over time. Integer Strategic Review
• Positive Sentiment: Market commentary highlighted that revenue beat and strength across key product lines drove a positive market reaction despite an EPS miss, supporting confidence in top-line momentum. Zacks Coverage
• Neutral Sentiment: Several analysts updated forecasts after the Q1 release; revisions are mixed and reflect differing views on margin recovery and the impact of the strategic review. Analyst Revisions
• Neutral Sentiment: Trading in ITGR was briefly halted as news was released, which can increase intraday volatility but does not change fundamentals. Q1 Results Release
• Negative Sentiment: Q1 EPS was $1.20, missing consensus by $0.01 and down from $1.31 a year ago; management set FY26 EPS guidance of $5.83–$6.40, below the street consensus (~$6.49), which raises near‑term execution concerns. Earnings Details
• Negative Sentiment: Citigroup trimmed its price target from $92 to $89 and moved to a “neutral” rating, reflecting more cautious near‑term sentiment and limiting upside from that broker’s client base. Citigroup Note

Analysts Set New Price Targets

ITGR has been the topic of a number of recent research reports. Piper Sandler reiterated an “overweight” rating and set a $97.00 price objective (up from $87.00) on shares of Integer in a research note on Friday. Truist Financial increased their price objective on shares of Integer from $95.00 to $97.00 and gave the company a “buy” rating in a research note on Friday, February 20th. Weiss Ratings upgraded shares of Integer from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Tuesday, February 24th. Citigroup lowered their price target on shares of Integer from $92.00 to $89.00 and set a “neutral” rating on the stock in a report on Friday. Finally, Wall Street Zen cut shares of Integer from a “buy” rating to a “hold” rating in a report on Sunday, January 25th. Four analysts have rated the stock with a Buy rating and six have given a Hold rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $98.29.

Insider Buying and Selling

In related news, VP Tommy P. Thomas sold 825 shares of the stock in a transaction that occurred on Friday, March 13th. The shares were sold at an average price of $85.00, for a total transaction of $70,125.00. Following the completion of the sale, the vice president owned 4,381 shares of the company’s stock, valued at $372,385. This represents a 15.85% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 1.10% of the stock is owned by insiders.

Institutional Investors Weigh In On Integer

Hedge funds and other institutional investors have recently bought and sold shares of the company. Salomon & Ludwin LLC purchased a new stake in Integer during the third quarter valued at approximately $26,000. Global Retirement Partners LLC lifted its position in Integer by 293.8% during the third quarter. Global Retirement Partners LLC now owns 319 shares of the medical equipment provider’s stock valued at $33,000 after acquiring an additional 238 shares during the last quarter. TD Private Client Wealth LLC raised its holdings in shares of Integer by 1,037.5% in the fourth quarter. TD Private Client Wealth LLC now owns 455 shares of the medical equipment provider’s stock worth $36,000 after buying an additional 415 shares during the last quarter. Parkside Financial Bank & Trust raised its holdings in shares of Integer by 135.5% in the fourth quarter. Parkside Financial Bank & Trust now owns 464 shares of the medical equipment provider’s stock worth $36,000 after buying an additional 267 shares during the last quarter. Finally, Arax Advisory Partners raised its holdings in shares of Integer by 2,489.5% in the fourth quarter. Arax Advisory Partners now owns 492 shares of the medical equipment provider’s stock worth $39,000 after buying an additional 473 shares during the last quarter. Hedge funds and other institutional investors own 99.29% of the company’s stock.

Integer Trading Down 5.4%

The stock’s fifty day simple moving average is $86.07 and its 200-day simple moving average is $81.76. The firm has a market cap of $2.85 billion, a PE ratio of 29.16, a PEG ratio of 1.50 and a beta of 0.71. The company has a debt-to-equity ratio of 0.77, a current ratio of 3.75 and a quick ratio of 2.23.

Integer Company Profile

Integer Holdings Corporation (NYSE: ITGR) is a global provider of outsourced medical device design, development and manufacturing solutions. The company partners with leading medical technology firms to deliver complex components, subsystems and finished devices across a range of therapeutic areas. Its services encompass concept and product design, precision machining, microelectronic assembly, terminal sterilization and regulatory support, enabling customers to accelerate time to market and optimize product performance.

Integer’s product portfolio is organized into two core segments: Advanced Delivery and MedTech.